On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act.
Among them is the blockbuster semaglutide, a prescription medication sold by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus for the treatment of Type 2 diabetes and obesity. The IRA required the federal government to publish the list of 15 drugs before Feb. 1, and so the Biden administration decided to act on its way out the door.
The makers of those 15 drugs have until Feb. 28 to decide whether to enter into negotiations with the government.
Read more at Newsmax© 2025 Newsmax. All rights reserved.
